The Efficacy of Subconjunctival Bevacizumab in the Management of Rubeosis Iridis and Neovascular Glaucoma

2019 ◽  
Vol 26 (1) ◽  
pp. 18-24
Author(s):  
Khatatbeh , Ahmed E. ◽  
Otoum , Marwan ◽  
Al Zweimel , Fawaz ◽  
Haddad , Hala ◽  
Rwashdeh , Hesham
Keyword(s):  
Neovascular Glaucoma ◽  
Rubeosis Iridis

Rubeosis iridis and macular hemorrhages from multiple Corkscrew retinal vessels in a patient with NF1

2021 ◽  
pp. 112067212199663
Author(s):  
Marilyn A Márquez ◽  
Claudio P Juárez ◽  
Maria C Sánchez ◽  
Jose D Luna
Keyword(s):  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Neovascular Glaucoma ◽  
Retinal Vessels ◽  
Retinal Hemorrhages ◽  
Fluorescein Angiogram ◽  
Rubeosis Iridis ◽  
Good Visual Outcome ◽  
Av Malformation ◽  
Sudden Decrease

Purpose: To report a case of a patient with NF1 presenting with ocular findings of AV malformation, multiple retinal hemorrhages, and neovascular glaucoma in the absence of retinal ischemia. Methods: Review of the medical record was conducted in accordance with the local IRBt. Results: A 60-year-old female patient with diagnosis of Neurofibromatosis type1 (NF1) and sudden decrease of vision in her left eye was found to have rubeosis iridis and high intraocular pressure (IOP). On fundus exam multiple corkscrew retinal vessels and retinal hemorrhages were present in her left eye. On Optical Coherence Tomography (OCT) the foveal hemorrhages appeared as outer layer hyperreflective retinal infiltrates whereas in the parafoveal area the hyperreflectivity was present between the RPE and neurosensory retina. Fluorescein Angiogram (FA) showed normal perfusion and no areas of leakage or ischemia. Treatment with anti-angiogenics in a timely manner correlated with a good visual outcome. Conclusions: We present a unique patient with NF1, rubeosis iridis, high IOP, and macular hemorrhages from multiple corkscrew retinal vessels in a well perfused retina, who underwent treatment with a single dose of intravitreal Bevacizumab and had an excellent response

Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in Neovascular Glaucoma

2011 ◽  
Vol 31 (2) ◽  
pp. 124-127 ◽  
Author(s):  
Ayse Gul Kocak Altintas ◽  
Hasan Basri Arifoglu ◽  
Esen Tutar ◽  
Gultekin Koklu ◽  
Pehmen Yasin Ozcan
Keyword(s):  
Anterior Chamber ◽  
Neovascular Glaucoma ◽  
Rubeosis Iridis ◽  
Bevacizumab Injection

scholarly journals An interesting case of rubeosis iridis with neovascular glaucoma in a young patient

2013 ◽  
Vol 69 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Avinash Mishra ◽  
Saurab Luthra ◽  
V.K. Baranwal ◽  
J.K.S. Parihar
Keyword(s):  
Young Patient ◽  
Neovascular Glaucoma ◽  
Interesting Case ◽  
Rubeosis Iridis

Rubeosis Iridis and Neovascular Glaucoma

1972 ◽  
Vol 74 (5) ◽  
pp. 862-867 ◽  
Author(s):  
Robert M. Feibel ◽  
John F. Bigger
Keyword(s):  
Neovascular Glaucoma ◽  
Rubeosis Iridis

Microvascular Injection Studies in Rubeosis Iridis and Neovascular Glaucoma

1977 ◽  
Vol 83 (4) ◽  
pp. 508-517 ◽  
Author(s):  
V.L. Jocson
Keyword(s):  
Neovascular Glaucoma ◽  
Rubeosis Iridis

Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma—results from a prospective interventional case series

2013 ◽  
Vol 251 (10) ◽  
pp. 2403-2413 ◽  
Author(s):  
Julia Lüke ◽  
Khaled Nassar ◽  
Matthias Lüke ◽  
Salvatore Grisanti
Keyword(s):  
Case Series ◽  
Neovascular Glaucoma ◽  
Rubeosis Iridis

scholarly journals Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis

2018 ◽  
Vol 9 (1) ◽  
pp. 243-247 ◽  
Author(s):  
Daisuke Sora ◽  
Kei Takayama ◽  
Manzo Taguchi ◽  
Tomohito Sato ◽  
Yutaka Sakurai ◽  
...  
Keyword(s):  
Topical Corticosteroid ◽  
Anterior Uveitis ◽  
Inflammatory Cells ◽  
Corticosteroid Treatment ◽  
Neovascular Glaucoma ◽  
Blurred Vision ◽  
Rubeosis Iridis ◽  
Granulomatous Uveitis ◽  
First Choice ◽  
Polymerase Chain

Purpose: We report a case of topical corticosteroid treatment-resolved rubeosis iridis with neovascular glaucoma (NVG) caused by noninfectious granulomatous uveitis. Case Report: A 61-year-old woman with left ocular pain and blurred vision was referred to our department. Visual acuity and intraocular pressure (IOP) were 20/60 and 37 mm Hg in the left eye, respectively. Inflammatory cells, hyphema, and rubeosis iridis were observed. All laboratory tests, including multiplex polymerase chain reaction for infection using aqueous humor, were negative, and there was neither retinal occlusive vasculitis nor retinal ischemia in the fundus. Our diagnosis was noninfectious granulomatous anterior uveitis-associated NVG. Topical corticosteroid treatment and anti-glaucoma agents resolved inflammation, rubeosis iridis, and NVG. IOP had decreased to 13 mm Hg by 1 month of treatment, and no recurrence was observed. Conclusion: Topical corticosteroid could resolve rubeosis iridis and NVG in an eye with noninfectious anterior uveitis. The pathogenesis of NVG in eyes with uveitis is still unknown, but inflammation might have a part in angiogenesis. Anti-inflammatory treatment can be selected as the first choice for anterior uveitis-associated NVG.

scholarly journals Penetration of Bevacizumab into the Iris, Anterior Chamber Angle and Ciliary Body After Intravitreal Injection

2009 ◽  
Vol 03 (01) ◽  
pp. 36
Author(s):  
Swaantje Peters ◽  
Peter Heiduschka ◽  
Karl-Ulrich Bartz-Schmidt ◽  
Ulrich Schraermeyer ◽  
◽  
...  
Keyword(s):  
Anterior Chamber ◽  
Intravitreal Injection ◽  
Ciliary Body ◽  
Anterior Segment ◽  
Intravitreal Bevacizumab ◽  
Neovascular Glaucoma ◽  
Anterior Chamber Angle ◽  
Rubeosis Iridis ◽  
Endothelial Growth Factor ◽  
Chamber Angle

Recently, it was suggested that the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab could be used in the treatment of rubeosis iridis. Therefore, we aimed to trace the penetration of bevacizumab into the anterior chamber after intravitreal injection of the drug. We found that intravitreally injected bevacizumab penetrates well and quickly into the anterior chamber angle, iris and ciliary body. The highest concentration of bevacizumab is present on days one to four after injection, with penetration into the iris appearing to be faster than that into the anterior chamber angle and ciliary body. These findings are consistent with the clinically described regression of iris neovascularisation one to three days after injection. Furthermore, we demonstrated progressive penetration through the tissues of the anterior chamber towards the sclera. Our study showed that the intravitreal application mode is suitable for obtaining an accumulation of bevacizumab throughout the vascularised tissues of the anterior segment. Intravitreal bevacizumab may be used as a supplementary treatment for rubeosis iridis and neovascular glaucoma.

Sign in / Sign up

Export Citation Format

Share Document